Nexturastat A
Product Code:
AG-CR1-3901
AG-CR1-3901
Product Group:
Inhibitors and Activators
Inhibitors and Activators
Supplier:
AdipoGen Life Sciences
AdipoGen Life Sciences
Regulatory Status:
RUO
RUO
Shipping:
Ambient
Ambient
Storage:
Short term: +4°C. Long term: -20°C
Short term: +4°C. Long term: -20°C
No additional charges, what you see is what you pay! *
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Related Products
- Show All
Further Information
Alternate Names/Synonyms:
4-((1-Butyl-3-phenylureido)methyl)-N-hydroxybenzamide
Appearance:
Light pink solid.
CAS:
1403783-31-2
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.Protect from light.
InChi:
InChI=1S/C19H23N3O3/c1-2-3-13-22(19(24)20-17-7-5-4-6-8-17)14-15-9-11-16(12-10-15)18(23)21-25/h4-12,25H,2-3,13-14H2,1H3,(H,20,24)(H,21,23)
InChiKey:
JZWXMCPARMXZQV-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1403783-31-2. Formula: C19H23N3O3. MW: 341.4. Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC50 =5.02nM). Displays high selectivity over all other HDACs (IC50=3-10µM). Suppresses cell proliferation and promotes apoptosis in B16 cells (GI50=14.3µM) and human lymphoma cells HuT-78. Dose-dependently induces hyperacetylation of alpha-tubulin in B16 murine melanoma cells without elevating histone H3 acetylation. Induces cell cycle arrest in G1. HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.
MDL:
MFCD28099804
Molecular Formula:
C19H23N3O3
Molecular Weight:
341.4
Package Type:
Vial
Product Description:
Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC50 =5.02nM). Displays high selectivity over all other HDACs (IC50=3-10µM). Suppresses cell proliferation and promotes apoptosis in B16 cells (GI50=14.3µM) and human lymphoma cells HuT-78. Dose-dependently induces hyperacetylation of alpha-tubulin in B16 murine melanoma cells without elevating histone H3 acetylation. Induces cell cycle arrest in G1. HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.
Purity:
>98% (HPLC)
SMILES:
CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC1=CC=CC=C1
Solubility Chemicals:
Soluble in DMSO. Slightly soluble in methanol or ethanol (1mg/ml). Almost insoluble in water.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
Documents
References
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth: J.A. Bergman, et al.; J. Med. Chem. 55, 9891 (2012) | Development and therapeutic implications of selective histone deacetylase 6 inhibitors: J.H. Kalin & J.A Bergman; J. Med. Chem. 56, 6297 (2013) | Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation: K.V. Woan, et al.; Mol. Oncol. 9, 1447 (2015) | Trend of histone deacetylase inhibitors in cancer therapy: Isoform selectivity or multitargeted strategy: L. Zhang, et al.; Med. Res. Rev. 35, 63 (2015) (Review)
Related Products
| Product Name | Product Code | Supplier | Nexturastat B | AG-CR1-3902 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACY-775 | AG-CR1-3903 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DMAPB | AG-CR1-3904 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PMPH | AG-CR1-3905 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DABPH | AG-CR1-3906 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MBIMPH | AG-CR1-3907 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MBIMPH F-Analog 1 . HCl | AG-CR1-3908 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MBIMPH F-Analog 2 | AG-CR1-3909 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



